The HSP60-ClpP interaction is therapeutically targetable, as demonstrated by the discovery of DCEM1, which blocks HSP60 interactions with ClpP, potentially providing an alternative approach to treat aggressive PCa that no longer responds to anti-AR therapy or genotoxic chemotherapy. The gene discussed is CLPP; the disease is posterior cortical atrophy.